Navigation Links
RuiYi et Genor BioPharma collaborent au développement du RYI-008 en Chine, un nouveau traitement contre les maladies auto-immunes et le cancer
Date:5/16/2013

ng Hi-Tech Park de Pudong, Shanghai, en Chine. Pour en savoir plus, rendez-vous sur www.ruiyibio.com.

À propos de Genor BioPharma

Fondée en 2007, Genor Biopharma Co. Ltd. est une société biopharmaceutique axée sur l'innovation et ayant pour vocation le développement et la commercialisation d'anticorps monoclonaux thérapeutiques (mAbs) et de protéines Fc-fusion. Grâce à un investissement total de près de 30 millions $, Genor dispose de plus de 10 produits dans sa gamme, dont trois sont en phase de DNR ou en phase clinique. Genor compte près de 110 employés, parmi lesquels des membres clés de l'équipe de gestion disposant d'une expertise et d'une expérience intégrées en matière de recherche et de développement de médicaments mAb et issus des plus grandes sociétés biotechnologiques et pharmaceutiques occidentales. Genor a bâti un centre de R&D de 6 000 m2, comprenant des laboratoires de R&D et de développement de processus, un centre analyse et qualité, ainsi qu'une installation de production clinique cGMP, et prévoir l'établissement d'une installation de production cGMP d'envergure commerciale. Pour en savoir plus, rendez-vous sur : http://www.genorbio.com.


'/>"/>
SOURCE RuiYi Inc.; Genor BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
2. CMC Biologics und RuiYi Enter treffen Vereinbarung zur Entwicklung eines neuartigen monoklonalen Anti-IL-6-Antikörpers
3. CMC Biologics et RuiYi passent un accord pour le développement dun nouvel anticorps monoclonal Anti-IL-6
4. CMC Biologics and RuiYi Enter into an Agreement for Development of a Novel Anti-IL-6 Monoclonal Antibody
5. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
6. Callidus Biopharma Announces $4.6 million in Series A Financing to Pursue Orphan Disease Therapies
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial Results
8. Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
9. PDL BioPharma to Announce First Quarter 2013 Financial Results on May 9, 2013
10. Rutgers Business School and the Blanche and Irwin Lerner Center will explore trends and issues facing the biopharmaceutical industry at a healthcare symposium, Tuesday, April 30
11. PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... New York , September 30, 2014 ... - Global Industry Analysis, Market Size, Share, Growth and ... is expected to be worth USD 20.8 billion in ... billion in 2017, growing at a CAGR of 7.3% ... fundamental elements needed for various health purposes, especially to ...
(Date:9/30/2014)... Sept. 30, 2014   Decision Resources Group ... data, anemic chronic kidney disease non-dialysis (CKD-ND) patients ... (ESA) medication. In addition, one-year persistency is similar ... Other key findings from the report entitled ... of Erythropoiesis Stimulating Agents in Late Stage Chronic ...
(Date:9/30/2014)... SAN DIEGO , 30. September ... Logo - http://photos.prnewswire.com/prnh/20130430/LA01948LOGO ... ein Medizintechnikunternehmen, das ein minimal-invasives 3D-Herzkammer-Bildgebungs- ... der Ursachen entwickelt, die zu komplexen ... aufrechterhalten, hat den Abschluss einer zusätzlichen ...
Breaking Medicine Technology:Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3
... (Becton, Dickinson and Company) (NYSE: BDX ) announced ... second fiscal quarter 2011 earnings conference call on Wednesday, April ... a press release detailing the quarter,s earnings after the market ... of the conference call, along with related slides, will be ...
... and HOUSTON, April 13, 2011 BD (Becton, Dickinson ... Management Healthcare Solutions, a subsidiary of Waste Management, Inc. ... to recycle medical sharps waste from hospitals and other ... ecoFinity™ Life Cycle Solution, an innovative service that will ...
Cached Medicine Technology:BD and Waste Management Launch Initiative to Recycle Medical Sharps 2BD and Waste Management Launch Initiative to Recycle Medical Sharps 3BD and Waste Management Launch Initiative to Recycle Medical Sharps 4
(Date:9/30/2014)... 30, 2014 Keystone Symposia will convene the first ... its 2014-15 Global Health Series on "The Modes ... Hotel immediately following the conclusion of the Grand ... is part of the Keystone Symposia Global Health Series, ... has also funded travel awards for 36 investigators from ...
(Date:9/30/2014)... York, NY (PRWEB) September 30, 2014 ... falling demand have hampered growth in the Bread ... diets have caused consumers to moderate their consumption ... consumer preferences for premium varieties shrunk the market ... products. Successful operators proactively responded by introducing more ...
(Date:9/30/2014)... Irvine, Calif., Sept. 30, 2014 Research by UC ... system functions, shedding light on a vital process that ... , In the online version of Nature Immunology ... Zhou and other Institute for Immunology colleagues describe a ... and released into the bloodstream. , A T cell ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 ... Blue Star Nutraceuticals designed to help maximize lean, strong ... optimizes the body’s absorption of glucose has caught the ... , “The main purpose behind Glycodrive is to help ... lean muscle,” reports Michaels. “Carbs are essential in the ...
(Date:9/30/2014)... Elevate , the latest product from Blue Start ... of the gym by providing natural ingredients that boost brain ... Michaels, prompting an investigative review. , “When it comes ... simply just don’t have the ability to perform the way ... the motivation to finish a project, or even feeling like ...
Breaking Medicine News(10 mins):Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UCI study uncovers important process for immune system development 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2
... the University of Pennsylvania School of Medicine have discovered ... of an important heart muscle protein called actin. Whats ... the pumping unit of the heart. The findings appear ... was known about Lmod when we began this study, ...
... JEFFERSONVILLE, Ind., April 10 Meijer customers ... carts. PetFirst,Healthcare LLC recently launched a partnership to ... throughout the Midwest., PetFirst insurance covers routine ... is now offered through cards displayed on freestanding ...
... band campaign, looks forward to taking ... April 10 Safe Kids Worldwide,the first-ever ... has named Mitchell R. Stoller as its ... announced today., (PHOTO: http://www.newscom.com/cgi-bin/prnh/20080410/DC19130-a ...
... and Exclusive Auction to be Held on Saturday, April 12th at the ... Helen Mills ... Kristin,Chenoweth, announced she will be performing a benefit concert on Saturday,April 12th ... The concert, titled, "Kristin Chenoweth, This One,s Personal: A,Concert to Stop ACD," ...
... ANA, Calif., April 10 Integrated,Healthcare Holdings, Inc. ... named Edward S. Gyimah as its Chief Compliance ... regulation of its,hospitals. Since 2006, Gyimah has worked ... instrumental in establishing and implementing the Company,s,Sarbanes-Oxley compliance ...
... of infants distinguish differences in sounds and it may ... start to speak, sparing them the difficulties that come ... Professor of Neuroscience April Benasich and her Infancy Studies ... and exciting clues about how infant brains begin to ...
Cached Medicine News:Health News:Penn researchers discover 'modus operandi' of heart muscle protein 2Health News:Meijer Supercenters to Offer PetFirst Insurance in Pet Aisles 2Health News:Safe Kids Worldwide Names Stoller New President, CEO 2Health News:Safe Kids Worldwide Names Stoller New President, CEO 3Health News:Kristin Chenoweth to Perform Benefit Concert for 3 Angels Memorial Fund titled, 'Kristin Chenoweth, This One's Personal: A Concert to Stop ACD' 2Health News:Kristin Chenoweth to Perform Benefit Concert for 3 Angels Memorial Fund titled, 'Kristin Chenoweth, This One's Personal: A Concert to Stop ACD' 3Health News:IHHI Announces Chief Compliance Officer Appointment 2Health News:Impairments in language development can be detected in infants as young as 3 months 2Health News:Impairments in language development can be detected in infants as young as 3 months 3
... stage is a refrigerated design for use as ... use with the 8000 sledge microtome, however, it ... refrigerated stage gives a large working area of ... to provide good adhesion between the specimen and ...
... For some sectioning work, it is necessary to ... State Freezer can be fitted to most microtomes ... -25C or lower, depending on conditions. The equipment ... unit. The cooling stage is best suited for ...
... is necessary to cool a specimen below room ... to most microtomes and will permit specimen cooling ... conditions. The equipment consists of a cooling stage ... best suited for operation with a base sledge ...
... MNL 4404 & 4405 series Freezing Stages fit ... have no moving parts and need only the ... for operation. Freezing starts immediately and ... adjustable so that optimum cutting temperatures can be ...
Medicine Products: